Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

GLIOBID

Financiado

Guiding glioblastoma treatments by decrypting tumor biomechanics via Magnetic Re...

Guiding glioblastoma treatments by decrypting tumor biomechanics via Magnetic Resonance Elastography. Glioblastoma multiforme (GBM) is the most common and deadly type of primary brain tumour, carrying a dire prognosis with a median survival of 14.6 months for patients undergoing standard treatments. The causes of poor clinical pro... ver más

31/03/2026

Innovasjon Norge

284K€

Presupuesto del proyecto: 284K€

Líder del proyecto

Innovasjon Norge No se ha especificado una descripción o un objeto social para esta compañía.

Ver 3 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-05-23

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021

I+D

Cerrada hace 3 años

0% 100%

3 Participantes

Innovasjon Norge

284.18K€ | Lider

BOARD OF TRUSTEES OF THE LEL...

STANFORD

N.D. | Participante

Proyectos interesantes

TIN2013-43457-R CARACTERIZACION DE FIRMAS BIOLOGICAS DE GLIOBLASTOMAS MEDIAN... 80K€ Cerrado

SAF2011-23870 MEJORA DE LOS PROTOCOLOS PARA DIAGNOSTICO Y SEGUIMIENTO DE R... 327K€ Cerrado

INTIGT Identification of novel targets to improve glioblastoma ther... 212K€ Cerrado

SAF2014-52332-R IMAGEN MOLECULAR DE GLIOMA DE ALTO GRADO PARA LA MEJORA DE L... 242K€ Cerrado

PTQ-12-05396 Identificación de nuevos biomarcadores de interés diagnóstic... 76K€ Cerrado

nPL4GBM Clinical validation of NANO-PL: a hydrogel-based formulation... 4M€ Cerrado

Últimas noticias

25-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 52 concesiones

25-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 1 concesiones

25-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 6 concesiones

Duración del proyecto: 46 meses Fecha Inicio: 2022-05-23
Fecha Fin: 2026-03-31

Líder del proyecto

Innovasjon Norge

Presupuesto del proyecto 284K€

Descripción del proyecto Glioblastoma multiforme (GBM) is the most common and deadly type of primary brain tumour, carrying a dire prognosis with a median survival of 14.6 months for patients undergoing standard treatments. The causes of poor clinical prognosis are late diagnosis, diffuse infiltration, pseudo necrosis, high neovascularization and resistance to therapy. In principle, drugs can reach the tumors via the vascular system, but the tumor microenvironment plays the role of an antagonist to any efficient drug delivery whereby reducing treatment efficacy. Recent treatments combine chemotherapy with drugs which aim at re-normalising the tumor microenvironment by releasing the mechanical pressure and/or by reducing the angiogenesis. However, there are yet no imaging biomarkers clinically available which can disentangle the different effects of the therapy on the components of the TME. This hinders patient management in particular dosage. GLIOBID project aim at disentangling the therapy impact on tissue integrity and pressure from the modulation of tumour vasculature by quantifying tissue rheology with magnetic resonance Elastography (MRE). This imaging breakthrough will allow to assess the effect of treatments on the main target – the tumor - and the pathways to reach it – the vessels and the tumour microenvironment - providing a unique guidance to tailor combined therapies based on component-specific biomarkers. GLIOBID will involve the main experts in the field of imaging and cancer biology, creating a highly multidisciplinary and eminently clinical environment. This together with the complementary expertise of researcher and hosting institutions will provide the best conditions for decrypting the complexity of the problem and find approaches translatable to the clinical routine. GLIOBID will potentially allow a paradigm shift from the current TREAT-THEN-OBSERVE approach to an OBSERVE-THUS-TREAT approach.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores